Cyberounds Logo
September 18, 2019 | LOGIN | REGISTER | HELP | 


email a friend print Bookmark and Share
Genetically Modified Foods: Scientific Perspective and Controversies
CME credit is no longer available for this conference.
Adrian Dubock, Ph.D.

Dr. Dubock is a member of the Advisory Board of the Freiburg Institute of Advanced Studies, School of Life Sciences and School of Soft Matter Research, Albert-Ludwigs-Universität, Freiburg, Germany. Formerly a senior executive of Syngenta responsible for Mergers, Acquisitions, Ventures and Intellectual Property Licensing, he is currently the Executive Secretary of the Golden Rice Humanitarian Board, and also Golden Rice Project Manager.

Dr. Dubock reports no commercial conflicts of interest.

Albert Einstein College of Medicine, CCME staff, and interMDnet staff have nothing to disclose.


Release Date: 11/18/2012
Termination Date: 11/18/2015

Estimated time to complete: 1 hour(s).

Albert Einstein College of Medicine designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Albert Einstein College of Medicine is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
 
Learning Objectives
Upon completion of this Cyberounds®, you should be able to:
  • Describe how a genetically modified crop differs from a conventionally bred crop
  • Describe the benefits of biofortification compared to fortification or supplementation as exemplified by Golden Rice
  • Discuss the scientific evidence for more or less caution with respect to genetically modified crops.

 
The opinions expressed herein are those of the author and do not necessarily represent the views of the sponsor or its publisher. Please review complete prescribing information of specific drugs or combination of drugs, including indications, contraindications, warnings and adverse effects before administering pharmacologic therapy to patients.
 
Please click below to accept the terms of this CME activity